PWM
HRMY icon

Parkworth Wealth Management’s Harmony Biosciences HRMY Stock Holding History

Parkworth Wealth Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$32 Hold
1
– – ﹤0.01% 1317
2025
Q1 		$33 Hold
1
– – ﹤0.01% 1164
2024
Q4 		$34 Buy
+1
New +$34 ﹤0.01% 1209

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parkworth Wealth Management's HRMY Position: Q2 2025 in Review

Parkworth Wealth Management held its Harmony Biosciences (HRMY) position steady in Q2 2025 at 1 share worth $32. The position accounts for ﹤0.01% of the portfolio, ranked #1317.

Parkworth Wealth Management first reported a position in HRMY in Q4 2024 and has held it in 3 quarters since. The position peaked at $34 in Q4 2024. 279 funds tracked by Wall St. Rank hold HRMY as of Q2 2025.

  • Parkworth Wealth Management held 1 share of Harmony Biosciences worth $32 as of Q2 2025.
  • Parkworth Wealth Management left its Harmony Biosciences share count unchanged in Q2 2025.
  • Harmony Biosciences made up ﹤0.01% of Parkworth Wealth Management's portfolio in Q2 2025, its #1317 holding.
  • Parkworth Wealth Management first reported a position in Harmony Biosciences in Q4 2024 and has held it in 3 quarters since.
  • Parkworth Wealth Management's Harmony Biosciences position peaked at $34 in Q4 2024.
  • 279 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2025.

Based on Parkworth Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.